NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
NeoGenomics (NASDAQ:NEO) has announced its financial guidance for 2025 and updated its Long-Range Financial Plan. The company expects total revenues of $735-745 million and adjusted EBITDA of $55-58 million for 2025, representing year-over-year growth of 11-13% and 43-51% respectively from 2024 midpoint guidance.
The company's Long-Range Plan targets include annual revenue growth of 12-13% with NGS growth of ~25% per year, gross margin expansion of 100-150 basis points annually, and adjusted EBITDA improvement of 250-300 basis points per year. NeoGenomics aims to achieve positive cash flow from operations in 2025 and serve more than 1 million patients annually by 2028.
The company plans to retire its 2025 convertible notes maturing on May 1, 2025, using cash on hand.
NeoGenomics (NASDAQ:NEO) ha annunciato le sue previsioni finanziarie per il 2025 e ha aggiornato il suo Piano Finanziario a Lungo Termine. L'azienda prevede ricavi totali di 735-745 milioni di dollari e un EBITDA rettificato di 55-58 milioni di dollari per il 2025, rappresentando una crescita anno su anno dell'11-13% e del 43-51% rispettivamente rispetto alla media delle previsioni del 2024.
Gli obiettivi del Piano a Lungo Termine dell'azienda includono una crescita annuale dei ricavi del 12-13% con una crescita NGS di circa il 25% all'anno, un'espansione del margine lordo di 100-150 punti base all'anno e un miglioramento dell'EBITDA rettificato di 250-300 punti base all'anno. NeoGenomics mira a raggiungere un flusso di cassa positivo dalle operazioni nel 2025 e a servire oltre 1 milione di pazienti all'anno entro il 2028.
L'azienda prevede di ritirare le sue obbligazioni convertibili 2025 in scadenza il 1° maggio 2025, utilizzando la liquidità disponibile.
NeoGenomics (NASDAQ:NEO) ha anunciado su guía financiera para 2025 y ha actualizado su Plan Financiero a Largo Plazo. La compañía espera ingresos totales de 735-745 millones de dólares y un EBITDA ajustado de 55-58 millones de dólares para 2025, lo que representa un crecimiento interanual del 11-13% y del 43-51% respectivamente desde la guía media de 2024.
Los objetivos del Plan a Largo Plazo de la compañía incluyen un crecimiento anual de ingresos del 12-13% con un crecimiento de NGS de aproximadamente el 25% por año, expansión del margen bruto de 100-150 puntos básicos anualmente y mejora del EBITDA ajustado de 250-300 puntos básicos por año. NeoGenomics tiene como objetivo alcanzar un flujo de caja positivo de las operaciones en 2025 y atender a más de 1 millón de pacientes anualmente para 2028.
La compañía planea retirar sus notas convertibles de 2025 que vencen el 1 de mayo de 2025, utilizando efectivo disponible.
NeoGenomics (NASDAQ:NEO)는 2025년 재정 가이드를 발표하고 장기 재무 계획을 업데이트했습니다. 이 회사는 2025년 총 수익이 7억 3천5백만에서 7억 4천5백만 달러와 조정된 EBITDA가 5천5백만에서 5천8백만 달러에 이를 것으로 예상하며, 이는 각각 2024년 중간 가이드 대비 연간 11-13% 및 43-51%의 성장률을 나타냅니다.
회사의 장기 계획 목표에는 연간 수익 성장률 12-13%, 연간 약 25%의 NGS 성장, 연간 100-150베이시스 포인트의 총마진 확대, 연간 250-300 베이시스 포인트의 조정 EBITDA 개선이 포함됩니다. NeoGenomics는 2025년에 운영에서 긍정적인 현금 흐름을 달성하고 2028년까지 연간 100만 명 이상의 환자를 치료하는 것을 목표로 하고 있습니다.
회사는 2025년 5월 1일 만기되는 2025년 전환사채를 사용 가능한 현금을 이용해 상환할 계획입니다.
NeoGenomics (NASDAQ:NEO) a annoncé ses prévisions financières pour 2025 et a mis à jour son Plan Financier à Long Terme. L'entreprise s'attend à un chiffre d'affaires total de 735-745 millions de dollars et un EBITDA ajusté de 55-58 millions de dollars pour 2025, représentant une croissance d'une année sur l'autre de 11-13% et 43-51% respectivement par rapport aux prévisions intermédiaires de 2024.
Les objectifs du Plan à Long Terme de l'entreprise incluent une croissance annuelle des revenus de 12-13% avec une croissance du NGS d'environ 25% par an, une expansion de la marge brute de 100-150 points de base par an, et une amélioration de l'EBITDA ajusté de 250-300 points de base par an. NeoGenomics vise à atteindre un flux de trésorerie positif provenant des opérations en 2025 et à servir plus d'un million de patients par an d'ici 2028.
L'entreprise prévoit de rembourser ses obligations convertibles 2025 arrivant à échéance le 1er mai 2025, en utilisant des liquidités disponibles.
NeoGenomics (NASDAQ:NEO) hat seine finanzielle Guidance für 2025 bekannt gegeben und seinen langfristigen Finanzplan aktualisiert. Das Unternehmen erwartet für 2025 Gesamterlöse von 735-745 Millionen US-Dollar und ein bereinigtes EBITDA von 55-58 Millionen US-Dollar, was ein jährliches Wachstum von 11-13% bzw. 43-51% im Vergleich zur prognostizierten Mittellinie 2024 darstellt.
Die Ziele des langfristigen Plans des Unternehmens beinhalten ein jährliches Umsatzwachstum von 12-13% mit einem NGS-Wachstum von etwa 25% pro Jahr, eine Erweiterung der Bruttomarge um 100-150 Basispunkte jährlich und eine Verbesserung des bereinigten EBITDA um 250-300 Basispunkte pro Jahr. NeoGenomics strebt an, im Jahr 2025 einen positiven Cashflow aus den Betrieben zu erreichen und bis 2028 über 1 Million Patienten jährlich zu betreuen.
Das Unternehmen plant, seine 2025 fälligen wandelbaren Anleihen, die am 1. Mai 2025 fällig werden, mit vorhandenen liquiden Mitteln zurückzukaufen.
- Projected revenue growth of 11-13% YoY for 2025
- Significant adjusted EBITDA growth of 43-51% YoY for 2025
- Expected NGS growth of ~25% annually
- Anticipated gross margin expansion of 100-150 bps per year
- Projected positive cash flow from operations starting 2025
- Strong cash position to retire 2025 convertible notes
- None.
Insights
NeoGenomics' 2025 guidance reveals a compelling growth trajectory with revenue projected at
The long-range plan's target of
The projected growth in patient volumes to serve over 1 million annually by 2028 indicates expanding market share in the oncology testing space. This volume-driven strategy, combined with margin expansion targets, creates a compelling operational leverage story. For retail investors, this presents a clear path to value creation through both top-line growth and bottom-line improvement.
The oncology testing market context makes these projections particularly noteworthy. NeoGenomics' focus on Next-Generation Sequencing (NGS) with
The company's transition to positive cash flow operations in 2025 represents a important inflection point. Think of it like a business that's been investing heavily in growth finally reaching the point where it can fund itself. The
The guidance suggests NEO is capturing market share in a fragmented industry while improving profitability - a rare combination that typically commands premium valuations. For context, serving 1 million patients annually would position them as one of the largest specialized oncology testing providers in the market.
-
Long-Range Plan reflects 12
-13% revenue growth annually - Presentation and webcast at 43rd Annual J.P. Morgan Healthcare Conference today, Wednesday, January 15, at 1:30 p.m. PT / 4:30 p.m. ET
“We enter 2025 with our patient-centric strategy in place, focusing on product innovation, further optimization and expansion of our commercial organization, and enhancing operational efficiencies,” said Chris Smith, chief executive officer of NeoGenomics. “Building on the strong momentum of double-digit revenue growth and margin expansion we have delivered over the last few years, we are updating our Long-Range Plan and now expect revenue growth of 12
2025 Financial Guidance
NeoGenomics is providing financial guidance1 for 2025. The Company expects total revenues in the range of
|
|
FY 2024 Guidance |
|
FY 2025 Guidance |
|
YoY % Change from FY'24 |
||||
|
|
|
|
|
|
|
|
|
|
|
($ millions) |
|
Midpoint |
|
Low |
|
High |
|
Low |
|
High |
Total Revenue |
|
|
|
|
|
|
|
|
|
|
Adj. EBITDA |
|
|
|
|
|
|
|
|
|
|
With a strong cash position, we currently expect to retire the 2025 convertible notes maturing on May 1, 2025, with cash on hand.
Long-Range Growth Plan
The Long-Range Plan builds upon the successful execution of the previous three years. NeoGenomics intends to achieve the following:
-
12
-13% revenue growth annually, including NGS growth of ~25% per year2 - Gross margin expansion of 100-150 bps per year
- Adjusted EBITDA improvement of 250-300 bps per year
- Positive cash flow from operations in 2025 and beyond
- Serving more than 1 million patients annually by 2028 and beyond
____________________
1 The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company’s securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.
2 Revenue growth excludes MRD
About NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115551011/en/
Investor Contact
Kendra Sweeney
Kendra.sweeney@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
Source: NeoGenomics, Inc.
FAQ
What is NeoGenomics' (NEO) revenue guidance for 2025?
What is NeoGenomics' (NEO) adjusted EBITDA guidance for 2025?
What is NeoGenomics' (NEO) long-term annual revenue growth target?
When will NeoGenomics (NEO) retire its convertible notes?
What is NeoGenomics' (NEO) patient service goal for 2028?
